humojo.wordpress.com
The Exton, Pa., biopharmaceutical company said it is restructuring its discovery group to focus on preclinical compounds, and allocating fewer resources to early-stagr programs. Adolor (NASDAQ:ADLR) said its primary focus going forward will continuse to be on its firstcommercial product, Entereg, which was launchecd in mid-2008, and on advancint its clinical programs. Entereg is used to acceleratre the recovery of upper and lower gastrointestina function in patients following boweoresection surgery. “This was a very difficult decisiojn forthe company,” said Michaep R. Dougherty, Adolor’s president and CEO.
“Given the broader economic conditions in our it is necessary for us to preserve our resources for the commercializationj of Entereg and the development of our The company expects the moved to reduce its annualized cash burn byabout $12 Based on its revised operating the company expects to end 2009 with about $85 millionh in cash and investments.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment